Based on the PCI BIOTECH ASA NK 3 stock forecast from 0 analysts, the average analyst target price for PCI BIOTECH ASA NK 3 is not available over the next 12 months. PCI BIOTECH ASA NK 3’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of PCI BIOTECH ASA NK 3 is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, PCI BIOTECH ASA NK 3’s stock price was EUR 0.10. PCI BIOTECH ASA NK 3’s stock price has changed by -9.03% over the past week, -11.89% over the past month and -36.36% over the last year.
No recent analyst target price found for PCI BIOTECH ASA NK 3
No recent average analyst rating found for PCI BIOTECH ASA NK 3
Company Overview PCI BIOTECH ASA NK 3
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases. In addition, the company develops fimaVACC for immunotherapy indications, which is in pre-clinical study; fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study for bioprocessing and dermatology indications; and technology for viral vector manufacturing and pre-clinical research for intratumoural immunotherapy. PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway. Read Less
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company's technology platform consists of a proprietary s...Read More
Frequently Asked Questions About PCI BIOTECH ASA NK 3 (4QG:F) Stock
Stock Target Advisor's fundamental analysis for PCI BIOTECH ASA NK 3's stock is Bearish.
Unfortunately we do not have enough data on 4QG:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4QG:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4QG:F's stock to indicate if its overvalued.
The last closing price of 4QG:F's stock was EUR 0.10.
The most recent market capitalization for 4QG:F is EUR 4.78M.
Unfortunately we do not have enough analyst data on 4QG:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains PCI BIOTECH ASA NK 3's stock.
As per our most recent records PCI BIOTECH ASA NK 3 has 6 Employees.
PCI BIOTECH ASA NK 3's registered address is UllernchaussEen 64, Oslo, Norway, 0379.
You can get more information about it from PCI BIOTECH ASA NK 3's website at https://www.pcibiotech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About PCI BIOTECH ASA NK 3 (4QG:F) Stock
Stock Target Advisor's fundamental analysis for PCI BIOTECH ASA NK 3's stock is Bearish.
Unfortunately we do not have enough data on 4QG:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4QG:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4QG:F's stock to indicate if its overvalued.
The last closing price of 4QG:F's stock was EUR 0.10.
The most recent market capitalization for 4QG:F is EUR 4.78M.
Unfortunately we do not have enough analyst data on 4QG:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains PCI BIOTECH ASA NK 3's stock.
As per our most recent records PCI BIOTECH ASA NK 3 has 6 Employees.
PCI BIOTECH ASA NK 3's registered address is UllernchaussEen 64, Oslo, Norway, 0379.
You can get more information about it from PCI BIOTECH ASA NK 3's website at https://www.pcibiotech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4QG:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
